AbbVie's ECLIPSE Study Revelations: Atogepant's Efficacy Against Migraine at European Headache Congress AbbVie has shared significant findings from the ECLIPSE study at the European Headache Congress, highlighting Atogepant's effectiveness in treating migraines.

AbbVie's ECLIPSE Study Revelations: Atogepant's Efficacy Against Migraine at European Headache Congress #USA #North_Chicago #Atogepant #ECLIPSE_Study #AQUIPTA

AbbVie Announces Encouraging Phase 3 ECLIPSE Study Results for Atogepant in Migraine Treatment AbbVie's Phase 3 ECLIPSE study reveals Atogepant's superiority to placebo in achieving pain freedom in acute migraine treatment, a significant advancement for patients.

AbbVie Announces Encouraging Phase 3 ECLIPSE Study Results for Atogepant in Migraine Treatment #United_States #AbbVie #North_Chicago #Atogepant #ECLIPSE_Study